Compare · ACN vs AHG
ACN vs AHG
Side-by-side comparison of Accenture plc (ACN) and Akso Health Group (AHG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACN and AHG operate in Real Estate (Real Estate), so they compete in similar markets.
- ACN is the larger of the two at $130.76B, about 159.0x AHG ($822.3M).
- Over the past year, ACN is down 37.5% and AHG is up 7.0% - AHG leads by 44.5 points.
- ACN has been more active in the news (23 items in the past 4 weeks vs 1 for AHG).
- ACN has more recent analyst coverage (25 ratings vs 0 for AHG).
- Company
- Accenture plc
- Akso Health Group
- Price
- $196.63+5.08%
- $1.68-5.10%
- Market cap
- $130.76B
- $822.3M
- 1M return
- +10.00%
- -17.28%
- 1Y return
- -37.48%
- +7.03%
- Industry
- Real Estate
- Real Estate
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- 2017
- News (4w)
- 23
- 1
- Recent ratings
- 25
- 0
Accenture plc
Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company also provides outsourcing services. It serves communications, media, high tech, software, and platform companies; banking, capital market, and insurance industries; and consumer goods, retail, travel services, industrial, and life science industries, as well as clients in health, public service, chemicals and natural resources, energy, and utility sectors. Accenture plc has alliance relationships with Adobe, Alibaba, Amazon Web Services, Blue Yonder, Cisco, Dell, Google, HPE, IBM RedHat, Microsoft, Oracle, Pegasystems, Salesforce, SAP, ServiceNow, VMWare, Workday, Massachusetts Institute of Technology, Institut Polytechnique de Paris, CNH Industrial, and Reactive Technologies. It has an agreement with Duke Energy Corporation for the development of a technology platform designed to measure actual baseline methane emissions from natural gas distribution systems. The company was incorporated in 2009 and is based in Dublin, Ireland.
Akso Health Group
Akso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, etc. It also offers consultancy and information technology support services; and trades in branded products, as well as promotes products. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Beijing, China. As of July 13, 2021, Akso Health Group operates as a subsidiary of Webao Limited.
Latest ACN
- Accenture downgraded by Truist with a new price target
- SEC Form SD filed by Accenture plc
- Mitsubishi Chemical and Accenture Establish Joint Venture to Drive AI-Enabled Business Reinvention and Operational Transformation
- HUMAIN and Accenture Accelerate AI Adoption at Scale Across Public and Private Sectors in Saudi Arabia
- Chief Leadership & HR Officer Clifford Katherine Lee was granted 51 units of Class A ordinary shares, increasing direct ownership by 0.80% to 6,433 units (SEC Form 4)
- Chief Operating Officer Hogan Catherine Kiernan was granted 54 units of Class A ordinary shares, increasing direct ownership by 0.41% to 13,202 units (SEC Form 4)
- Director Brudermueller Martin was granted 9 units of Class A ordinary shares, increasing direct ownership by 0.54% to 1,681 units (SEC Form 4)
- Chief Accounting Officer Burgum Melissa A was granted 23 units of Class A ordinary shares, increasing direct ownership by 0.27% to 8,467 units (SEC Form 4)
- Director Uotani Masahiko was granted 9 units of Class A ordinary shares, increasing direct ownership by 0.73% to 1,249 units (SEC Form 4)
- CEO-The Americas Walsh John F was granted 25 units of Class A ordinary shares, increasing direct ownership by 0.10% to 25,569 units (SEC Form 4)
Latest AHG
- SEC Form 6-K filed by Akso Health Group
- AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology
- SEC Form 3 filed by new insider Xie Zhongliang
- SEC Form 3 filed by new insider Xu Jianqiang
- SEC Form 3 filed by new insider Liu Wenjuan
- SEC Form 6-K filed by Akso Health Group
- SEC Form 3 filed by Akso Health Group
- SEC Form 3 filed by Akso Health Group
- SEC Form 3 filed by Akso Health Group
- SEC Form 6-K filed by Akso Health Group